Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 3(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07722962Phase 3Not Yet Recruiting

Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Role: lead

NCT05627648Phase 3Active Not Recruiting

Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar

Role: lead

NCT04475224Phase 3Unknown

Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

Role: lead

NCT02193334Phase 1Completed

Phase I/II Study of KP-100IT in Acute Spinal Cord Injury

Role: lead

NCT00797706Phase 1Unknown

Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers

Role: collaborator

All 5 trials loaded